Integra LifeSciences Q1 Earnings Call Highlights

Key Points

• Q1 beat and guidance change: Integra reported Q1 revenue of $392 million and adjusted EPS of $0.54, both above the high end of guidance, and raised full-year adjusted EPS to $2.40–$2.50 after a favorable tariff (IEEPA) outcome that added roughly $0.02 in Q1.
• Leadership shift and commercial emphasis: Chairman Stuart Essig has resumed the role of President & CEO, and the company appointed Mike McBreen as its first Chief Commercial Officer to raise the profile and coordination of market-facing functions.
• Segment performance and financial outlook: Tissue Reconstruction grew about 6% organically while Specialty Surgery was down ~0.6% organic, management kept full-year revenue guidance at $1.66–$1.70 billion and expects margin improvement and progress toward reducing leverage toward its 2.5–3.5x target.

Integra LifeSciences NASDAQ: IART reported first-quarter 2026 results that exceeded the high end of management’s guidance ranges, while also outlining leadership changes and reiterating its full-year revenue outlook.

Leadership transition and commercial emphasis

Chairman Stuart Essig said he has “stepped back into the role as President and CEO” and will retain his role as Chairman. Essig thanked outgoing CEO Mojdeh Poul and credited her with advancing initiatives including “enterprise-wide portfolio and program prioritization,” a “risk-based approach to quality remediation work,” and “operations resiliency improvements,” along with transformation and business process optimization efforts.

Essig told analysts the decision for Poul to step down “was mutual between her and the board,” adding that while there were “differences in certain strategic topics,” transformation initiatives put in place will continue unchanged.

As part of organizational changes, Essig announced the appointment of Mike McBreen as the company’s first Chief Commercial Officer, calling the role an effort to elevate commercial priorities at the leadership level. Essig said the change is “not about changing direction in the commercial organization,” but about “raising its profile” and improving coordination across market-facing functions. When asked whether the company would expand the sales force, Essig said the move does not imply higher or lower sales headcount and is focused on consistency in how Integra presents itself to customers.

Q1 results top guidance; EPS outlook raised on tariffs

For the first quarter, Integra posted revenue of $392 million and adjusted earnings per share of $0.54. Essig said both were “above the high end of our guidance ranges.”

CFO Lea Knight said first-quarter revenue increased 2.4% on a reported basis and 1.3% organically, citing “solid product demand, improving supply execution and remediation, and the continued positive impact of our transformation.” Adjusted EPS rose from $0.41 in the prior-year quarter to $0.54, which Knight attributed primarily to revenue growth, favorable product mix, and transformation-related savings.

Knight also noted a tariff impact in the quarter, describing a “$0.02 net tariff benefit driven by the anticipated IEEPA refund, partially offset by non-IEEPA tariffs expensed in the period.” On the Q&A, she said tariffs contributed to EPS upside in the quarter and that Integra raised its full-year adjusted EPS guidance by $0.10 “as a result of favorable tariff outcomes in the first quarter relative to our February guidance.” She added that Integra has not assumed additional tariff favorability beyond what was realized in Q1 given uncertainty around future policy.

Profitability improved year over year. Gross margin was 64.1%, up 190 basis points, reflecting “favorable product mix, IEEPA tariffs, and reductions in remediation costs,” according to Knight. Adjusted EBITDA margin was 19.4%, up 280 basis points, with benefits from margin drivers and transformation efforts. Operating cash flow was $9.8 million, and capital expenditures were $14.8 million.

Segment performance: Tissue Reconstruction growth offsets Specialty Surgery softness

Integra also renamed its global business segments, with Codman Specialty Surgical now called Specialty Surgery and Tissue Technologies renamed Tissue Reconstruction. Knight said product brand names will remain unchanged.

• Specialty Surgery: Revenue was $283 million, up 0.9% reported, including a 140-basis-point foreign exchange benefit. Organic revenue declined 0.6% year over year.
• Tissue Reconstruction: Revenue was $109 million, up 6.7% reported and 6.4% organically, partially offset by the impact of MediHoney, which had been sold in Q1 2025 prior to a recall.

Within Specialty Surgery, Global Neurosurgery delivered 1.9% organic growth, supported by demand for Certas Plus, CUSA, and Bactiseal. Knight said capital equipment grew low single digits, including double-digit growth in CUSA and CereLink, while instruments declined at a high single-digit rate due primarily to order timing. In ENT, revenue declined low single digits as growth in MicroFrance ENT instruments was offset by pressure in sinus wounds and commercial disruption impacts in other products. International markets declined low single digits, with demand offset by supply timing.

In Tissue Reconstruction, Knight said wound reconstruction franchise sales increased 6.2%, driven by double-digit growth in Integra Skin, mid-double-digit growth in DuraSorb, and the PriMatrix launch. She said private label sales increased 7.1% primarily due to a favorable comparison, while international Tissue Reconstruction revenue declined high single digits as double-digit growth in Integra Skin was offset by MediHoney.

Medicare skin substitute reimbursement changes: limited exposure, potential upside

Knight addressed CMS reimbursement changes for skin substitutes in the outpatient wound reconstruction market, emphasizing that “approximately 90% of our wound reconstruction revenue is generated from the inpatient market” and that the inpatient market “is not impacted by these changes.”

She said Integra believes the updated framework could “level the economic playing field and create upside opportunities,” noting the company’s portfolio is priced in line with the new outpatient reimbursement rate of $127 per square centimeter, with multiple size options and clinical evidence. During Q&A, Knight said Integra has not had to change pricing and has not seen a margin impact tied to outpatient reimbursement changes. She also said the company is seeing early indications of incremental volume opportunities as physicians seek education on product selection and sizing.

Guidance maintained on revenue; margin cadence outlined

Integra maintained its full-year 2026 revenue guidance of $1.66 billion to $1.7 billion, with organic growth expected at 0.8% to 3.3%. Second-quarter revenue guidance was set at $410 million to $425 million, implying reported growth of -1.3% to 2.3% and organic growth of -1.5% to 2.1%.

Adjusted EPS guidance for Q2 was $0.44 to $0.52. For the full year, Integra raised adjusted EPS guidance to $2.40 to $2.50. Knight said operational expectations were unchanged from earlier guidance, and at the midpoint of updated guidance the company expects gross margin and adjusted EBITDA margin to improve 60 basis points and 100 basis points, respectively, versus 2025.

Knight said Integra expects a sequential revenue step-up in Q2 of about $26 million from Q1, driven by normal seasonality, supply improvement, and instrument order timing, with modest sequential growth in Q3 and a further increase in Q4. She also described expected gross margin variability through the year, with full-year gross margin expected at about 62.5%, Q2 below that level, a modest step-up in Q3, and Q4 above the full-year average due to tariffs and manufacturing variances.

On the balance sheet, Knight said net debt was $1.6 billion at March 31, with a consolidated total leverage ratio of 4.1x, within the company’s maximum allowable leverage of 5x. She said Integra expects to continue reducing leverage over the year, “approaching the upper end” of its 2.5x to 3.5x target leverage range by the end of 2026. Total liquidity was about $488 million, including $266 million in cash and short-term investments.

Looking ahead, Essig said Integra expects to start production at its Braintree facility by the end of June and to relaunch SurgiMend by the end of the year. Management also discussed advancing a PMA strategy for SurgiMend and DuraSorb in implant-based breast reconstruction. Knight said SurgiMend is expected to be ready for pre-approval inspection in the second half of 2026, with PMA approval expected sometime in 2027, followed by DuraSorb “shortly thereafter” in 2027, while noting there is no PMA contribution embedded in 2026 guidance.

About Integra LifeSciences NASDAQ: IART

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.